Global Leukemia Antibodies Market Report 2022-2028: Featuring Key Players AstraZeneca, GlaxoSmithKline, Janssen Pharmaceuticals, Pfizer & Others
Saturday, July 9, 2022
DUBLIN, July 6, 2022 /PRNewswire/ -- The "Global Leukemia Antibodies Market, Drug Sales & Clinical Trials Insight 2028" report has been added to ResearchAndMarkets.com's offering.
http://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
The global leukemia antibody therapeutics market is expected to surpass US$ 4 Billion by 2028. Several factors are boosting the growth of the market including the increasing burden of leukemia cases, the high unmet medical need for cancer therapy, and rising investment in healthcare sectors. Moreover, a large number of investments made in this segment have enabled pharmaceutical companies to develop more enhanced antibody therapeutics for the management of leukemia.
The encouraging response of these therapeutics has propelled further research and development activities in this domain. Presently, more than 100 clinical trials are ongoing in the global leukemia antibody therapeutics market. US is currently holding the maximum number of clinical trials in the market which is mainly attributed to the presence of major key players in the region associated with their huge investments in this segment.
Apart from US, China is also making huge investments in antibody therapeutics to cope up with the market growth. The China pharmaceutical market is also expanding at large rates owing to the presence of both domestic as well as international players. The growth is reliant on supportive government policies, favorable healthcare coverage rates, advancements in medical technology, and new product launches in the market.
However, it is estimated that bispecific antibodies will emerge as a potential therapeutic option in the management of leukemia owing to their enhanced efficacy and specificity in the management of the disease. Although only one bispecific antibody has entered the market, their robust pipeline suggests that several bispecific antibodies will gain entry into the market during the forecast period, thus boosting this segment.
Report Highlights:
-- Leukemia Cancer Antibodies Market Global and Regional Outlook
-- Global Leukemia Cancer Antibodies Market Opportunity > USD 4 Billion
-- Global and Regional Sales AnalysisLeukemia Cancer Antibody Drug
Conjugates, Monoclonal Antibodies, Bispecific Antibodies Insight
-- Pricing, Dosage, Patent Insight On Approved Leukemia Cancer Antibodies
-- Comprehensive Insight On More Than 100 Leukemia Cancer Antibodies in
Clinical Trials
-- Leukemia Cancer Antibodies in Clinical Trials Insight By Phase, Company,
Orphan Designation
Key Topics Covered:
1. Research Methodology
2. Global Leukemia Antibody Market Overview
2.1 Current Market Scenario
2.2 Regional Market Analysis
2.3 Future Market Opportunity
3. Global Leukemia Antibodies Clinical Trials Overview
3.1 By Company
3.2 By Country
3.3 By Phase
3.4 By Patient Segment
4. Leukemia Antibody Drug Conjugates Insight
4.1 Overview
4.2 Drugs Availability, Patent, Price & Dosage Analysis
5. Leukemia Monoclonal Antibody Insight
5.1 Overview
5.2 Drugs Availability, Patent, Price & Dosage Analysis
6. Leukemia Bispecific Antibody Insight
6.1 Overview
6.2 Drugs Availability, Patent, Price & Dosage Analysis
7. Global Leukemia Antibodies - Global & Regional Sales Analysis
7.1 Besponsa
7.2 Rituxan
7.3 Gazyva
7.4 Blincyto
8. Global Leukaemia Antibodies Clinical Pipeline by Company, Indication & Phase
8.1 Research
8.2 Preclinical
8.3 Phase-I
8.4 Phase-I/Ii
8.5 Phase-Ii
8.6 Phase-Iii
8.7 Preregistration
8.8 Registered
9. Marketed Leukaemia Antibodies Clinical, Patent & Orphan Designation Insight
Companies Mentioned
-- Amgen
-- Amphivena Therapeutics
-- AstraZeneca
-- Eli Lilly
-- GlaxoSmithKline
-- Innovent
-- Janssen Pharmaceuticals
-- Jasper Therapeutics
-- Pfizer
-- Roche
For more information about this report visit https://www.researchandmarkets.com/r/tm2x3n
Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Logo: http://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/global-leukemia-antibodies-market-report-2022-2028-featuring-key-players-astrazeneca-glaxosmithkline-janssen-pharmaceuticals--pfizer--others-301581336.html
SOURCE Research and Markets
|
|
|
|
|
 |
Weekly Recap: 11 Tech Press Releases You Need to See | Jan 22, 2026
|
|
Sup AI Sets New Benchmark Record with 52.15% on Humanity's Last Exam | Jan 22, 2026
|
|
Skunk Works® and XTEND Expand Joint All Domain Command and Control for Advanced Mission Execution | Jan 22, 2026
|
|
DEADLINE ANNOUNCED FOR 2026 NEW TOP-LEVEL DOMAIN APPLICATIONS | Jan 22, 2026
|
|
Trigent Partners with WeWork India to Expand its GCC Footprint | Jan 22, 2026
|
|
Altair HyperWorks 2026 Delivers Design and Simulation at Scale with AI | Jan 22, 2026
|
|
Exia Labs Brings Keystone to the U.S. Navy via DIU's Blue Object Management Challenge | Jan 22, 2026
|
|
Glasswall Brings Defense-Level File Sanitization to Every Government Agency and Business Using Microsoft 365 | Jan 22, 2026
|
|
Marketing Evolution Announces New Investment Led by Insight Partners to Power AI-Ready Marketing Data for the Agentic Era | Jan 22, 2026
|
|
Genpact Named a Leader in ISG Provider Lens(TM) 2025 for Insurance GCCs and Agentic AI Services | Jan 22, 2026
|
|
|
